Stock Price & Analysis

Based on the provided data and current market conditions, here's a comprehensive analysis of CNC stock:

Technical Analysis

The stock is showing a bullish trend in the pre-market with a +1.16% increase. Current technical indicators suggest:

• RSI-14 at 40.77 indicates neutral territory but approaching oversold conditions
• MACD (-1.38) shows bearish momentum with a potential crossover
• Stock is trading below both SMA-200 (67.57) and SMA-50, indicating bearish long-term trend

Fundamental Analysis

Recent developments and outlook:

• Analysts maintain a "Moderate Buy" rating with 10 "Strong Buy," 6 "Hold," and 1 "Moderate Sell" recommendations
• Mean price target of $78.09 suggests a 28.6% upside potential from current levels
• Barclays maintains highest price target of $93, implying 53.1% upside

Key Catalysts

• Government proposed 2.2% increase in Medicare Advantage payments for 2026, with total payment increase estimated at 4.3% or over $21 billion
• Company issued minimum adjusted EPS guidance of $7.25 for fiscal 2025
• Recent insider buying activity (7 purchases) signals management confidence

Recommendation SELL at current levels. Despite positive analyst sentiment and insider buying, technical indicators suggest continued downward pressure. The stock has underperformed both the broader market and healthcare sector peers, declining 18% over the past 52 weeks. Wait for technical indicators to show clear reversal signals before entering long positions.

Based on the provided data and market analysis, here's the price prediction for CNC stock in 2025:

Technical Analysis

• Current price is trading at $58.35 in pre-market [Relevant Data]
• The stock is showing bearish momentum with RSI-14 at 40.77, indicating a neutral to slightly bearish sentiment
• Price is trading below all major moving averages (SMA 5,10,20,60,200,250), suggesting a strong downtrend
• Bollinger Bands show price near the lower band, with potential support at $50.33

Fundamental Drivers & Catalysts

• Medicare Advantage payment rates proposed to increase by 4.3% or over $21 billion in 2026, which could positively impact CNC's revenues
• Wall Street analysts maintain a "Moderate Buy" rating with a mean price target of $78.09, representing a 28.6% upside potential
• The company provided 2025 minimum adjusted EPS guidance of $7.25, with consensus at $7.32

Price Target Scenarios for 2025:

• Base Case: $78-80 range, supported by:

  • Analyst consensus price target
  • Expected earnings growth and Medicare Advantage rate increases
  • Current attractive valuation at <9x forward earnings

• Bear Case: $55-58 range if:

  • Medical costs continue rising above expectations
  • Political uncertainty impacts government healthcare programs
  • Market sentiment remains negative on healthcare sector

• Bull Case: $90-93 range (Barclays target) if:

  • Medical cost ratio improves
  • Medicare Advantage enrollment grows significantly
  • Political environment becomes more favorable

Most likely scenario points to the base case of $78-80 by end of 2025, representing approximately 35% upside from current levels, driven by favorable Medicare Advantage rates and attractive valuation multiples.

The S1 support level for CNC Stock is $55.71 ,The R1 resistant level for CNC Stock is $60.54.

As of the end of day on 2025-02-26, the price of CNC Stock was $57.

The target price for CNC Stock according to analyst rating is 77.04, with the highest price target at 93.00 and the lowest at 53.00. Analysts have a Moderate Buy rating on CNC Stock overall.

The market cap of CNC is $28.2B.

Based on the provided data and recent market analysis, here are 5 key points about CNC's valuation:

Centene appears fairly valued at current levels considering its strong fundamentals and growth prospects. The company's net income doubled from $1.2B in 2022 to $2.7B in 2023, demonstrating robust earnings growth.

Technical indicators show CNC is currently trading near support levels with RSI at 40.77 and below all major moving averages (SMA 20/60/200), suggesting the stock may be oversold at current prices.

The stock is trading at a significant discount to analyst price targets, with a mean target of $78.09 representing 28.6% upside potential, supported by 10 "Strong Buy" ratings out of 17 analysts.

CNC's valuation metrics have improved, with net margin expanding from 0.83% to 1.75% YoY and ROE more than doubling from 4.73% to 10.83%, indicating enhanced operational efficiency.

The company's strong revenue growth to $154B in 2023 and improved current ratio of 1.11 suggest solid financial health, though the stock has underperformed the broader market with an 18% decline over the past year.

Centene Corporation is a healthcare company. The Company provides services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. It provides a range of managed healthcare products and services, primarily through Medicaid, Medicare, and commercial products. Its segments include Medicaid, Medicare, Commercial and Other. It offers Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. It also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Medicaid program provides health insurance to low-income families and individuals with disabilities. Medicare is a federal health insurance program for people ages 65 and over, which also covers people under 65 with certain disabilities and people with end-stage renal diseases.

Based on the available data and market analysis, here's the 2030 price prediction for CNC stock:

Centene Corporation (CNC) stock is projected to reach $115-120 by 2030, representing approximately a 100% upside from current levels of $58.35, driven by expected growth in the US health insurance market which is forecast to reach $639 billion by 2033. The company's strong position in government-sponsored healthcare programs and expanding commercial marketplace business, combined with its current attractive valuation trading at less than 9x forward earnings, supports this long-term target. However, potential regulatory changes after future elections could impact growth trajectory.

CNC has a total of 67700 employees.